Annual EBIT
$79.01 M
+$30.13 M+61.65%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual earnings before interest & taxes is $79.01 million, with the most recent change of +$30.13 million (+61.65%) on December 31, 2023.
- During the last 3 years, PCRX annual EBIT has risen by +$35.41 million (+81.20%).
- PCRX annual EBIT is now -7.48% below its all-time high of $85.40 million, reached on December 31, 2021.
Performance
PCRX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$135.01 M
-$174.71 M-440.03%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly earnings before interest & taxes is -$135.01 million, with the most recent change of -$174.71 million (-440.03%) on September 30, 2024.
- Over the past year, PCRX quarterly EBIT has dropped by -$154.39 million (-796.56%).
- PCRX quarterly EBIT is now -429.06% below its all-time high of $41.03 million, reached on June 30, 2023.
Performance
PCRX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$42.60 M
-$154.39 M-138.11%
September 30, 2024
Summary
- As of February 7, 2025, PCRX TTM earnings before interest & taxes is -$42.60 million, with the most recent change of -$154.39 million (-138.11%) on September 30, 2024.
- Over the past year, PCRX TTM EBIT has dropped by -$76.72 million (-224.88%).
- PCRX TTM EBIT is now -137.67% below its all-time high of $113.11 million, reached on March 31, 2024.
Performance
PCRX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
PCRX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.6% | -796.6% | -224.9% |
| 3 y3 years | +81.2% | -925.2% | -151.5% |
| 5 y5 years | +297.2% | -925.2% | -151.5% |
PCRX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -7.5% | +61.6% | -429.1% | at low | -137.7% | at low |
| 5 y | 5-year | -7.5% | +607.2% | -429.1% | at low | -137.7% | at low |
| alltime | all time | -7.5% | +237.0% | -429.1% | at low | -137.7% | +34.9% |
Pacira BioSciences EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$135.01 M(-440.0%) | -$42.60 M(-138.1%) |
| Jun 2024 | - | $39.70 M(+144.0%) | $111.78 M(-1.2%) |
| Mar 2024 | - | $16.27 M(-55.3%) | $113.11 M(+43.2%) |
| Dec 2023 | $79.01 M(+61.6%) | $36.42 M(+87.9%) | $79.01 M(+131.6%) |
| Sep 2023 | - | $19.38 M(-52.8%) | $34.12 M(+32.5%) |
| Jun 2023 | - | $41.03 M(-330.2%) | $25.76 M(+75.3%) |
| Mar 2023 | - | -$17.82 M(+110.4%) | $14.70 M(-69.9%) |
| Dec 2022 | $48.88 M(-42.8%) | -$8.47 M(-176.9%) | $48.88 M(-19.6%) |
| Sep 2022 | - | $11.02 M(-63.2%) | $60.80 M(-24.6%) |
| Jun 2022 | - | $29.97 M(+83.2%) | $80.67 M(-2.5%) |
| Mar 2022 | - | $16.36 M(+374.6%) | $82.72 M(-3.1%) |
| Dec 2021 | $85.40 M(+95.9%) | $3.45 M(-88.8%) | $85.40 M(-15.5%) |
| Sep 2021 | - | $30.90 M(-3.5%) | $101.07 M(+22.0%) |
| Jun 2021 | - | $32.01 M(+68.1%) | $82.82 M(+70.7%) |
| Mar 2021 | - | $19.04 M(-0.4%) | $48.51 M(+11.2%) |
| Dec 2020 | $43.60 M(+290.3%) | $19.11 M(+51.0%) | $43.61 M(+64.5%) |
| Sep 2020 | - | $12.65 M(-650.4%) | $26.52 M(+95.6%) |
| Jun 2020 | - | -$2.30 M(-116.3%) | $13.56 M(-39.6%) |
| Mar 2020 | - | $14.14 M(+599.3%) | $22.44 M(+100.8%) |
| Dec 2019 | $11.17 M(-43.8%) | $2.02 M(-763.0%) | $11.17 M(-51.0%) |
| Sep 2019 | - | -$305.00 K(-104.6%) | $22.81 M(-17.5%) |
| Jun 2019 | - | $6.58 M(+128.8%) | $27.65 M(-3.5%) |
| Mar 2019 | - | $2.88 M(-78.9%) | $28.66 M(+44.1%) |
| Dec 2018 | $19.89 M(-177.1%) | $13.66 M(+201.7%) | $19.89 M(+27.8%) |
| Sep 2018 | - | $4.53 M(-40.3%) | $15.57 M(+89.4%) |
| Jun 2018 | - | $7.59 M(-228.9%) | $8.22 M(-157.7%) |
| Mar 2018 | - | -$5.89 M(-163.1%) | -$14.25 M(-44.8%) |
| Dec 2017 | -$25.80 M(-17.8%) | $9.34 M(-431.4%) | -$25.80 M(-31.1%) |
| Sep 2017 | - | -$2.82 M(-81.1%) | -$37.43 M(-32.3%) |
| Jun 2017 | - | -$14.88 M(-14.7%) | -$55.29 M(+18.3%) |
| Mar 2017 | - | -$17.45 M(+662.6%) | -$46.74 M(+48.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2016 | -$31.39 M(-440.1%) | -$2.29 M(-88.9%) | -$31.39 M(+4.7%) |
| Sep 2016 | - | -$20.68 M(+227.2%) | -$29.98 M(+616.5%) |
| Jun 2016 | - | -$6.32 M(+200.0%) | -$4.18 M(-205.4%) |
| Mar 2016 | - | -$2.11 M(+140.3%) | $3.97 M(-57.0%) |
| Dec 2015 | $9.23 M(-256.8%) | -$877.00 K(-117.1%) | $9.23 M(-48.7%) |
| Sep 2015 | - | $5.12 M(+179.1%) | $17.98 M(+53.2%) |
| Jun 2015 | - | $1.83 M(-41.8%) | $11.74 M(+72.8%) |
| Mar 2015 | - | $3.15 M(-60.0%) | $6.79 M(-218.6%) |
| Dec 2014 | -$5.88 M(-89.8%) | $7.88 M(-802.0%) | -$5.73 M(-76.4%) |
| Sep 2014 | - | -$1.12 M(-64.0%) | -$24.23 M(-32.7%) |
| Jun 2014 | - | -$3.11 M(-66.8%) | -$36.00 M(-20.0%) |
| Mar 2014 | - | -$9.37 M(-11.8%) | -$45.00 M(-22.0%) |
| Dec 2013 | -$57.69 M(+14.3%) | -$10.62 M(-17.6%) | -$57.69 M(-8.5%) |
| Sep 2013 | - | -$12.89 M(+6.4%) | -$63.07 M(-3.7%) |
| Jun 2013 | - | -$12.12 M(-45.1%) | -$65.47 M(+7.1%) |
| Mar 2013 | - | -$22.06 M(+37.9%) | -$61.16 M(+21.2%) |
| Dec 2012 | -$50.47 M(+30.9%) | -$16.00 M(+4.7%) | -$50.47 M(+3.8%) |
| Sep 2012 | - | -$15.29 M(+96.0%) | -$48.63 M(+15.6%) |
| Jun 2012 | - | -$7.80 M(-31.4%) | -$42.08 M(-0.7%) |
| Mar 2012 | - | -$11.38 M(-19.7%) | -$42.36 M(+11.2%) |
| Dec 2011 | -$38.55 M(+66.2%) | -$14.16 M(+62.2%) | -$38.11 M(+28.7%) |
| Sep 2011 | - | -$8.73 M(+8.0%) | -$29.60 M(+6.9%) |
| Jun 2011 | - | -$8.09 M(+13.5%) | -$27.69 M(+9.7%) |
| Mar 2011 | - | -$7.12 M(+25.8%) | -$25.23 M(+11.0%) |
| Dec 2010 | -$23.19 M(-18.8%) | -$5.66 M(-17.0%) | -$22.73 M(-8.6%) |
| Sep 2010 | - | -$6.82 M(+21.2%) | -$24.88 M(+2.9%) |
| Jun 2010 | - | -$5.63 M(+22.0%) | -$24.17 M(+30.3%) |
| Mar 2010 | - | -$4.62 M(-40.9%) | -$18.55 M(+33.1%) |
| Dec 2009 | -$28.55 M(-37.1%) | -$7.81 M(+27.6%) | -$13.93 M(+127.6%) |
| Sep 2009 | - | -$6.12 M | -$6.12 M |
| Dec 2008 | -$45.36 M | - | - |
FAQ
- What is Pacira BioSciences annual earnings before interest & taxes?
- What is the all time high annual EBIT for Pacira BioSciences?
- What is Pacira BioSciences annual EBIT year-on-year change?
- What is Pacira BioSciences quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Pacira BioSciences?
- What is Pacira BioSciences quarterly EBIT year-on-year change?
- What is Pacira BioSciences TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Pacira BioSciences?
- What is Pacira BioSciences TTM EBIT year-on-year change?
What is Pacira BioSciences annual earnings before interest & taxes?
The current annual EBIT of PCRX is $79.01 M
What is the all time high annual EBIT for Pacira BioSciences?
Pacira BioSciences all-time high annual earnings before interest & taxes is $85.40 M
What is Pacira BioSciences annual EBIT year-on-year change?
Over the past year, PCRX annual earnings before interest & taxes has changed by +$30.13 M (+61.65%)
What is Pacira BioSciences quarterly earnings before interest & taxes?
The current quarterly EBIT of PCRX is -$135.01 M
What is the all time high quarterly EBIT for Pacira BioSciences?
Pacira BioSciences all-time high quarterly earnings before interest & taxes is $41.03 M
What is Pacira BioSciences quarterly EBIT year-on-year change?
Over the past year, PCRX quarterly earnings before interest & taxes has changed by -$154.39 M (-796.56%)
What is Pacira BioSciences TTM earnings before interest & taxes?
The current TTM EBIT of PCRX is -$42.60 M
What is the all time high TTM EBIT for Pacira BioSciences?
Pacira BioSciences all-time high TTM earnings before interest & taxes is $113.11 M
What is Pacira BioSciences TTM EBIT year-on-year change?
Over the past year, PCRX TTM earnings before interest & taxes has changed by -$76.72 M (-224.88%)